Evidence map›Paper›PMID 34919514›Full record

ArticleMicrobial genomics2021

Worldwide distribution and environmental origin of the Adelaide imipenemase (AIM-1), a potent carbapenemase in

Anteneh Amsalu, Sylvia A Sapula, Jonathan J Whittall, Bradley J Hart, Jan M Bell, John Turnidge, Henrietta Venter

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbial genomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Global epidemiology of carbapenem-resistantJAC-antimicrobial resistance · 2026
    Review
  2. Article
  3. Article
  4. Revisiting the Metallo-International journal of microbiology · 2025
    Review
  5. Article
  6. Article
  7. Heliyon · 2024
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Anteneh AmsaluUniSA Clinical and Health Sciences, Health and Biomedical Innovation, University of South Australia, Adelaide, Australia.
Sylvia A SapulaUniSA Clinical and Health Sciences, Health and Biomedical Innovation, University of South Australia, Adelaide, Australia.
Jonathan J WhittallUniSA Clinical and Health Sciences, Health and Biomedical Innovation, University of South Australia, Adelaide, Australia.
Bradley J HartUniSA Clinical and Health Sciences, Health and Biomedical Innovation, University of South Australia, Adelaide, Australia.
Jan M BellAustralian Centre for Antimicrobial Ecology, The University of Adelaide, Adelaide, Australia.
John TurnidgeAdelaide Medical School, University of Adelaide, Adelaide, Australia.
Henrietta VenterUniSA Clinical and Health Sciences, Health and Biomedical Innovation, University of South Australia, Adelaide, Australia.
University of South Australia · AUThe University of Adelaide · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carbapenems are potent broad-spectrum β-lactam antibiotics reserved for the treatment of serious infections caused by multidrug-resistant bacteria such as

Indexed as

Drug Resistance, BacterialAmino Acid SequenceAnimalsAsiaBacterial Proteinsbeta-LactamasesCarbapenemsEuropeHigh-Throughput Nucleotide SequencingHumansMicrobial Sensitivity TestsNorth AmericaPhylogenyPhylogeographyPseudomonas aeruginosaWastewaterBacterial Proteinsbeta-lactamase AIM-1, Pseudomonas aeruginosabeta-LactamasesCarbapenemsWastewaterAdelaide imipenemase (AIM-1)antimicrobial resistancecarbapenem resistancePseudomonas aeruginosaPseudoxanthomonas mexicana

Identifiers

PMID34919514
PMCPMC8767344
OpenAlexW4200364782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.